CoChat

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Open access
Höglinger, Günter U, Litvan, Irene, Mendonca, Nuno, Wang, Deli, Zheng, Hui, Rendenbach-Mueller, Beatrice, Lon, Hoi-Kei, Jin, Ziyi, Fisseha, Nahome, Budur, Kumar, Gold, Michael, Ryman, Davis, Florian, Hana, Ahmed, Anwar, Aiba, Ikuko, Albanese, Alberto, Bertram, Kelly, Bordelon, Yvette, Bower, James, Brosch, Jared, Claassen, Daniel, Colosimo, Carlo, Corvol, Jean-Christophe, Cudia, Paola, Daniele, Antonio, Defebvre, Luc, Driver-Dunckley, Erika, Duquette, Antoine, Eleopra, Roberto, Eusebio, Alexandre, Fung, Victor, Geldmacher, David, Golbe, Lawrence, Grandas, Francisco, Hall, Deborah, Hatano, Taku, Höglinger, Günter U, Honig, Lawrence, Hui, Jennifer, Kerwin, Diana, Kikuchi, Akio, Kimber, Thomas, Kimura, Takashi, Kumar, Rajeev, Litvan, Irene, Ljubenkov, Peter, Lorenzl, Stefan, Ludolph, Albert, Mari, Zoltan, McFarland, Nikolaus, Meissner, Wassilios, Mir Rivera, Pablo, Mochizuki, Hidek, Morgan, John, Munhoz, Renato, Nishikawa, Noriko, O`Sullivan, John, Oeda, Tomoko, Oizumi, Hideki, Onodera, Osamu, Ory-Magne, Fabienne, Peckham, Elizabeth, Postuma, Ronald, Quattrone, Aldo, Quinn, Joseph, Ruggieri, Stefano, Sarna, Justyna, Schulz, Paul E, Slevin, John, Tagliati, Michele, Wile, Daryl, Wszolek, Zbigniew, Xie, Tao, Zesiewicz, Theresa · 2021 · The Lancet Neurology
Cited by 145

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND Progressive supranuclear palsy is a neurodegenerative disorder associated with tau protein aggregation. Tilavonemab (ABBV-8E12) is a monoclonal antibody that binds to the N-terminus of human tau. We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy. METHODS We did a phase 2, multicentre, randomised, placebo-controlled, double-blind study at 66 hospitals and clinics in Australia, Canada, France, Germany, Italy, Japan, Spain, and the USA. Participants (aged ≥40 years) diagnosed with possible or probable progressive supranuclear palsy who were symptomatic for less than 5 years, had a reliable study partner, and were able to walk five steps with minimal assistance, were randomly assigned (1:1:1) by interactive response technology to tilavonemab 2000 mg, tilavonemab 4000 mg, or matching placebo administered intravenously on days 1, 15, and 29, then every 28 days through to the end of the 52-week treatment period. Randomisation was done by the randomisation specialist of the study sponsor, who did not otherwise participate in the study. The sponsor, investigators, and participants were unaware of treatment allocations. The primary endpoint was the change from baseline to week 52 in the Progressive Supranuclear Palsy Rating Scale (PSPRS) total score in the intention-to-treat population. Adverse events were monitored in participants who received at least one dose of study drug. Prespecified interim futility criteria were based on a model-based effect size of 0 or lower when 60 participants had completed the 52-week treatment period and 0·12 or lower when 120 participants had completed the 52-week treatment period. This study is registered at ClinicalTrials.gov, number NCT02985879. FINDINGS Between Dec 12, 2016, and Dec 31, 2018, 466 participants were screened, 378 were randomised. The study was terminated on July 3, 2019, after prespecified futility criteria were met at the second interim analysis. A total of 377 participants received at least one dose of study drug and were included in the efficacy and safety analyses (2000 mg, n=126; 4000 mg, n=125; placebo, n=126). Least squares mean change from baseline to week 52 in PSPRS was similar in all groups (between-group difference vs placebo: 2000 mg, 0·0 [95% CI -2·6 to 2·6], effect size 0·000, p>0·99; 4000 mg, 1·0 [-1·6 to 3·6], -0·105, p=0·46). Most participants reported at least one adverse event (2000 mg, 111 [88%]; 4000 mg, 111 [89%]; placebo, 108 [86%]). Fall was the most common adverse event (2000 mg, 42 [33%]; 4000 mg, 54 [43%]; placebo, 49 [39%]). Proportions of patients with serious adverse events were similar among groups (2000 mg, 29 [23%]; 4000 mg, 34 [27%]; placebo, 33 [26%]). Fall was the most common treatment-emergent serious adverse event (2000 mg, five [4%]; 4000 mg, six [5%]; placebo, six [5%]). 26 deaths occurred during the study (2000 mg, nine [7%]; 4000 mg, nine [7%]; placebo, eight [6%]) but none was drug related. INTERPRETATION A similar safety profile was seen in all treatment groups. No beneficial treatment effects were recorded. Although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear palsy. FUNDING AbbVie Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(20)30489-0

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 145

Metadata

Authors
Höglinger, G. U., Litvan, I., Mendonca, N., Wang, D., Zheng, H., Rendenbach-Mueller, B., Lon, H.-K., Jin, Z., Fisseha, N., Budur, K., Gold, M., Ryman, D., Florian, H., Ahmed, A., Aiba, I., Albanese, A., Bertram, K., Bordelon, Y., Bower, J., Brosch, J., Claassen, D., Colosimo, C., Corvol, J.-C., Cudia, P., Daniele, A., Defebvre, L., Driver-Dunckley, E., Duquette, A., Eleopra, R., Eusebio, A., Fung, V., Geldmacher, D., Golbe, L., Grandas, F., Hall, D., Hatano, T., Höglinger, G. U., Honig, L., Hui, J., Kerwin, D., Kikuchi, A., Kimber, T., Kimura, T., Kumar, R., Litvan, I., Ljubenkov, P., Lorenzl, S., Ludolph, A., Mari, Z., McFarland, N., Meissner, W., Mir Rivera, P., Mochizuki, H., Morgan, J., Munhoz, R., Nishikawa, N., O`Sullivan, J., Oeda, T., Oizumi, H., Onodera, O., Ory-Magne, F., Peckham, E., Postuma, R., Quattrone, A., Quinn, J., Ruggieri, S., Sarna, J., Schulz, P. E., Slevin, J., Tagliati, M., Wile, D., Wszolek, Z., Xie, T., & Zesiewicz, T.
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2021-03
Volume
20
Issue
3
Pages
182-192
ISSN
1474-4422 (ISSN-L)
OpenAlex
W3133453048
Cited by
145
References
12
FWCI
10.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s1474-4422(20)30489-0
The paper
Höglinger, G. U., Litvan, I., Mendonca, N., Wang, D., Zheng, H., Rendenbach-Mueller, B., Lon, H.-K., Jin, Z., Fisseha, N., Budur, K., Gold, M., Ryman, D., Florian, H., Ahmed, A., Aiba, I., Albanese, A., Bertram, K., Bordelon, Y., Bower, J., . . . Zesiewicz, T. (2021). Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(20)30489-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.